<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00939822</url>
  </required_header>
  <id_info>
    <org_study_id>2015-0038</org_study_id>
    <secondary_id>R01AG031790-01A1</secondary_id>
    <secondary_id>H-2009-0030</secondary_id>
    <secondary_id>H-2008-0275</secondary_id>
    <nct_id>NCT00939822</nct_id>
  </id_info>
  <brief_title>Statin Effects on Beta-Amyloid and Cerebral Perfusion in Adults at Risk for Alzheimer's Disease</brief_title>
  <acronym>SHARP</acronym>
  <official_title>Statin Effects on Beta-Amyloid and Cerebral Perfusion in Adults at Risk for AD: &quot;Statins in Healthy, At-Risk Adults: Impact on Amyloid and Regional Perfusion (SHARP)&quot; Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the research is to see how simvastatin affects a substance in the body called
      beta-amyloid. Beta-amyloid is found in the brain and in the liquid around the brain and
      spinal cord. High amounts of beta-amyloid may be associated with a greater risk of getting
      Alzheimer's disease. This study will see if simvastatin can lower the amount of beta-amyloid
      in the spinal fluid. This study will also see if simvastatin affects memory and thinking,
      blood flow in the brain, and blood vessel function. The investigators hope that future
      studies show whether simvastatin might prevent memory loss and decrease the chance of
      developing Alzheimer's disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Studies show that some medicines that lower cholesterol may reduce the risk of developing
      Alzheimer's disease, but this has not yet been proven in humans. We are looking for
      individuals to participate in this study to see if a cholesterol-lowering medication, called
      simvastatin affects blood flow to the brain, blood vessel function and a substance in the
      spinal fluid related to the changes in Alzheimer's disease.

      The SHARP study included 88 adults ages 40-72 with parental history of documented Alzheimer's
      disease. The study had 9 visits over the course of 18 months. Participants had fasting blood
      tests collected, completed a medical history questionnaire and medication side effect review,
      underwent lumbar puncture procedure, completed memory testing, and had ultrasound and MRI
      procedures. Participants were randomly assigned to receive either simvastatin or a placebo
      each night for 18 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2009</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Cerebrospinal Fluid (CSF) Beta-amyloid-42 Levels Compared to Baseline as Measured by xMAP</measure>
    <time_frame>Baseline and 18 months</time_frame>
    <description>Change in CSF beta-amyloid-42 was defined as the ratio of 18-month levels to baseline levels.
Beta-amyloid-42 is a substance found in the plaques in the brain of people with Alzheimer's disease and can be detected in CSF. There is no defined normal range yet for middle-aged adults.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in CSF Beta-amyloid-40 Levels as Measured by xMAP (Multi-Analyte Profiling) )</measure>
    <time_frame>Baseline and 18 months</time_frame>
    <description>Change in CSF beta-amyloid-40 was defined as the ratio of 18-month levels to baseline levels.
Beta amyloid-40 is a substance found in the brain vessels of individuals with Alzheimer's disease and has more potent cerebrovascular effects on individuals with Alzheimer's disease than any other form of beta amyloid.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in CSF Soluble Alpha Precursor Proteins (sAPP-alpha) and Soluble Beta Precursor Proteins (sAPP-beta) as Measured by Duplex</measure>
    <time_frame>Baseline and 18 months</time_frame>
    <description>Changes in CSF sAPP-alpha and sAPP-beta were defined as the ratio of 18-month levels to baseline levels.
sAPP-alpha and sAPP-beta are components of beta-amyloid that provide information on beta-amyloid breakdown.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in CSF Total Tau (T-tau) and Phosphorylated Tau (P-tau) as Measured by xMAP</measure>
    <time_frame>Baseline and 18 months</time_frame>
    <description>Changes in CSF t-tau and p-tau were defined as the ratio of 18-month levels to baseline levels.
T-tau and p-tau are substances found in the brain that can provide information on nerve cell health in the brain and tangle formation in nerve cells.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Simvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg. Simvastatin/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>40 mg Simvastatin/day</description>
    <arm_group_label>Simvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Parent diagnosed with Alzheimer's disease

          -  Age 40-72

        Exclusion Criteria:

          -  Active liver disease

          -  History of adverse reaction to statins

          -  Contraindication to lumbar puncture

          -  Elevated creatine kinase and creatinine lab values

          -  Use of medications known to interact with statins

          -  History of dementia or mild cognitive impairment

          -  Currently pregnant or planning to become pregnant

          -  Use of large quantities of grapefruit juice (more than 1 quart per day)

          -  Contraindications to MRI (for MRI sub-study)

          -  Currently on cholesterol-lowering medication or use in past 4 months

          -  History of heart attack, heart problems, stroke and/or diabetes

          -  Drinking more than a quart of grapefruit juice per day

          -  Metal implants, or metal debris in body (MRI)

          -  List of medications that interact with simvastatin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>72 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cynthia M. Carlsson, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>UW Madison School of Medicine and Public Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karen Lazar</name>
      <address>
        <city>Fitchburg</city>
        <state>Wisconsin</state>
        <zip>53711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://wisconsinadrc.wisc.edu/</url>
    <description>Related Info</description>
  </link>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 14, 2009</study_first_submitted>
  <study_first_submitted_qc>July 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2009</study_first_posted>
  <results_first_submitted>June 14, 2019</results_first_submitted>
  <results_first_submitted_qc>August 2, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 9, 2019</results_first_posted>
  <last_update_submitted>August 2, 2019</last_update_submitted>
  <last_update_submitted_qc>August 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Asymptomatic middle-aged adults (ages 40-72 years) with parental history of AD were recruited from the community through local memory clinics, newsletters, educational talks, booths at health fairs, and newspaper and magazine advertisements.</recruitment_details>
      <pre_assignment_details>Screened individuals were not randomized to drug or placebo if they withdrew consent, were unable to complete baseline procedures or no longer met inclusion criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Simvastatin</title>
          <description>40 mg. Simvastatin/day
Simvastatin: 40 mg Simvastatin/day</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Matching Placebo
Placebo: Matching Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>withdrew from study due to busy schedule</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Mental health issues</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Simvastatin</title>
          <description>40 mg. Simvastatin/day
Simvastatin: 40 mg Simvastatin/day</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Matching Placebo
Placebo: Matching Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
            <count group_id="B2" value="44"/>
            <count group_id="B3" value="88"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.95" spread="6.2"/>
                    <measurement group_id="B2" value="54.4" spread="7.8"/>
                    <measurement group_id="B3" value="55.21" spread="6.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in Cerebrospinal Fluid (CSF) Beta-amyloid-42 Levels Compared to Baseline as Measured by xMAP</title>
        <description>Change in CSF beta-amyloid-42 was defined as the ratio of 18-month levels to baseline levels.
Beta-amyloid-42 is a substance found in the plaques in the brain of people with Alzheimer's disease and can be detected in CSF. There is no defined normal range yet for middle-aged adults.</description>
        <time_frame>Baseline and 18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin</title>
            <description>40 mg. Simvastatin/day
Simvastatin: 40 mg Simvastatin/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching Placebo
Placebo: Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Cerebrospinal Fluid (CSF) Beta-amyloid-42 Levels Compared to Baseline as Measured by xMAP</title>
          <description>Change in CSF beta-amyloid-42 was defined as the ratio of 18-month levels to baseline levels.
Beta-amyloid-42 is a substance found in the plaques in the brain of people with Alzheimer's disease and can be detected in CSF. There is no defined normal range yet for middle-aged adults.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" lower_limit="0.96" upper_limit="1.07"/>
                    <measurement group_id="O2" value="0.98" lower_limit="0.95" upper_limit="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in CSF Beta-amyloid-40 Levels as Measured by xMAP (Multi-Analyte Profiling) )</title>
        <description>Change in CSF beta-amyloid-40 was defined as the ratio of 18-month levels to baseline levels.
Beta amyloid-40 is a substance found in the brain vessels of individuals with Alzheimer's disease and has more potent cerebrovascular effects on individuals with Alzheimer's disease than any other form of beta amyloid.</description>
        <time_frame>Baseline and 18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin</title>
            <description>40 mg. Simvastatin/day
Simvastatin: 40 mg Simvastatin/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching Placebo
Placebo: Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in CSF Beta-amyloid-40 Levels as Measured by xMAP (Multi-Analyte Profiling) )</title>
          <description>Change in CSF beta-amyloid-40 was defined as the ratio of 18-month levels to baseline levels.
Beta amyloid-40 is a substance found in the brain vessels of individuals with Alzheimer's disease and has more potent cerebrovascular effects on individuals with Alzheimer's disease than any other form of beta amyloid.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" lower_limit="0.99" upper_limit="1.07"/>
                    <measurement group_id="O2" value="0.98" lower_limit="0.94" upper_limit="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in CSF Soluble Alpha Precursor Proteins (sAPP-alpha) and Soluble Beta Precursor Proteins (sAPP-beta) as Measured by Duplex</title>
        <description>Changes in CSF sAPP-alpha and sAPP-beta were defined as the ratio of 18-month levels to baseline levels.
sAPP-alpha and sAPP-beta are components of beta-amyloid that provide information on beta-amyloid breakdown.</description>
        <time_frame>Baseline and 18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin</title>
            <description>40 mg. Simvastatin/day
Simvastatin: 40 mg Simvastatin/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching Placebo
Placebo: Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in CSF Soluble Alpha Precursor Proteins (sAPP-alpha) and Soluble Beta Precursor Proteins (sAPP-beta) as Measured by Duplex</title>
          <description>Changes in CSF sAPP-alpha and sAPP-beta were defined as the ratio of 18-month levels to baseline levels.
sAPP-alpha and sAPP-beta are components of beta-amyloid that provide information on beta-amyloid breakdown.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>sAPP-alpha</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" lower_limit="0.92" upper_limit="1.00"/>
                    <measurement group_id="O2" value="1.03" lower_limit="0.97" upper_limit="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sAPP-beta</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" lower_limit="0.93" upper_limit="1.02"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.97" upper_limit="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in CSF Total Tau (T-tau) and Phosphorylated Tau (P-tau) as Measured by xMAP</title>
        <description>Changes in CSF t-tau and p-tau were defined as the ratio of 18-month levels to baseline levels.
T-tau and p-tau are substances found in the brain that can provide information on nerve cell health in the brain and tangle formation in nerve cells.</description>
        <time_frame>Baseline and 18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin</title>
            <description>40 mg. Simvastatin/day
Simvastatin: 40 mg Simvastatin/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching Placebo
Placebo: Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in CSF Total Tau (T-tau) and Phosphorylated Tau (P-tau) as Measured by xMAP</title>
          <description>Changes in CSF t-tau and p-tau were defined as the ratio of 18-month levels to baseline levels.
T-tau and p-tau are substances found in the brain that can provide information on nerve cell health in the brain and tangle formation in nerve cells.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total tau</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" lower_limit="0.97" upper_limit="1.05"/>
                    <measurement group_id="O2" value="1.01" lower_limit="0.98" upper_limit="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphorylated tau</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.16" lower_limit="0.90" upper_limit="1.42"/>
                    <measurement group_id="O2" value="1.15" lower_limit="1.00" upper_limit="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Simvastatin</title>
          <description>40 mg. Simvastatin/day
Simvastatin: 40 mg Simvastatin/day</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Matching Placebo
Placebo: Matching Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Cynthia M. Carlsson</name_or_title>
      <organization>University of Wisconsin School of Medicine and Public Health</organization>
      <phone>608-256-1901 ext 11691</phone>
      <email>cmc@medicine.wisc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

